Chemical Exchange Saturation Transfer MR Imaging is Superior to Diffusion-Tensor Imaging in the Diagnosis and Severity Evaluation of Parkinson’s Disease: A Study on Substantia Nigra and Striatum by Chunmei Li et al.
October 2015 | Volume 7 | Article 1981
Original research
published: 19 October 2015
doi: 10.3389/fnagi.2015.00198
Frontiers in Aging Neuroscience | www.frontiersin.org
Edited by: 
Atsushi Takeda, 
National Hospital Organization, 
Sendai-Nishitaga Hospital
Reviewed by: 
Graziella Madeo, 
University of Rome Tor Vergata, Italy 
Silmar Teixeira, 
Federal University of Piauí, Brazil
*Correspondence:
Min Chen 
chenmin62@yahoo.com
Received: 29 June 2015
Accepted: 04 October 2015
Published: 19 October 2015
Citation: 
Li C, Wang R, Chen H, Su W, Li S, 
Zhao X, Zhou J, Qiao J, Lou B, 
Song G and Chen M (2015) Chemical 
exchange saturation transfer MR 
imaging is superior to diffusion-tensor 
imaging in the diagnosis and severity 
evaluation of Parkinson’s disease: 
a study on substantia 
nigra and striatum. 
Front. Aging Neurosci. 7:198. 
doi: 10.3389/fnagi.2015.00198
chemical exchange saturation 
transfer Mr imaging is superior to 
diffusion-tensor imaging in the 
diagnosis and severity evaluation of 
Parkinson’s disease: a study on 
substantia nigra and striatum
Chunmei Li1 , Rui Wang1 , Haibo Chen2 , Wen Su2 , Shuhua Li2 , Xuna Zhao3,4 , Jinyuan 
Zhou3 , Jian Qiao1 , Baohui Lou1 , Guodong Song1 and Min Chen1*
1 Department of Radiology, Beijing Hospital, Beijing, China, 2 Department of Neurology, Beijing Hospital, Beijing, China, 
3 Department of Radiology, Johns Hopkins University, Baltimore, MD, USA, 4 Philips Healthcare, Beijing, China
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by nigrostriatal 
cell loss. To date, the diagnosis of PD is still based primarily on the clinical manifesta-
tions, which may be typical and obvious only in advanced-stage PD. Thus, it is crucial 
to find a reliable marker for the diagnosis of PD. We conducted this study to assess 
the diagnostic efficiency of chemical exchange saturation transfer (CEST) imaging and 
diffusion-tensor imaging (DTI) in PD at 3 T by evaluating changes on substantia nigra 
and striatum. Twenty-three PD patients and twenty-three age-matched normal controls 
were recruited. All patients and controls were imaged on a 3-T MR system, using an 
eight-channel head coil. CEST imaging was acquired in two transverse slices of the 
head, including substantia nigra and striatum. The magnetization transfer ratio asym-
metry at 3.5  ppm, MTRasym(3.5  ppm), and the total CEST signal intensity between 0 
and 4 ppm were calculated. Multi-slice DTI was acquired for all the patients and normal 
controls. Quantitative analysis was performed on the substantia nigra, globus pallidus, 
putamen, and caudate. The MTRasym(3.5  ppm) value, the total CEST signal intensity,
and fractional anisotropy value of the substantia nigra were all significantly lower in PD 
patients than in normal controls (P = 0.003, P = 0.004, and P < 0.001, respectively). 
The MTRasym(3.5 ppm) values of the putamen and the caudate were significantly higher 
in PD patients than in normal controls (P = 0.010 and P = 0.009, respectively). There 
were no significant differences for the mean diffusivity in these four regions between PD 
patients and normal controls. In conclusion, CEST MR imaging provided multiple CEST 
image contrasts in the substantia nigra and the striatum in PD and may be superior to 
DTI in the diagnosis of PD.
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inTrODUcTiOn
Parkinson’s disease (PD) is a neurodegenerative disorder char-
acterized by nigrostriatal cell loss, resulting in striatal dopamine 
deficiency (Dauer and Przedborski, 2003). Accurate diagnosis 
in early stage of PD and early initiation of therapy may provide 
benefit for the patient (Olanow et  al., 2009). Unfortunately, 
to date, the diagnosis of PD is still based primarily on the 
clinical manifestations, which may be typical and obvious only 
in advanced-stage PD. Thus, it is crucial to find a reliable marker 
for the diagnosis of PD.
Several functional MR imaging have been used to assist in the 
PD diagnosis, including diffusion-tensor imaging (DTI). Based 
on the diffusivity of water molecules, which exhibit a varying 
degree of tissue dependent anisotropy, two primary DTI param-
eters, fractional anisotropy (FA) and mean diffusivity (MD) or 
apparent diffusion coefficient (ADC), are associated with the 
directionality (anisotropy) and magnitude (diffusivity) of water 
diffusion, respectively (Hagmann et al., 2006). DTI has typically 
been used to detect axon and myelin injury in white matter of 
PD patients (Cnyrim et al., 2014; Kamagata et al., 2014), while 
some studies have also focused on evaluating the abnormalities 
in gray matter (Prakash et al., 2012; Zhan et al., 2012; Lenfeldt 
et al., 2013).
Recently, a relatively new MR technique, chemical exchange 
saturation transfer (CEST) imaging (Zhou and van Zijl, 2006; 
Kogan et al., 2013; Vinogradov et al., 2013), or more specifically, 
amide proton transfer (APT) MR imaging (Zhou et al., 2003), has 
been used to assess PD (Li et al., 2014). CEST imaging is a specific 
type of magnetization transfer imaging [that is sensitive to solid-
like proteins in tissue (van Buchem and Tofts, 2000; Henkelman 
et al., 2001)]. It has recently emerged as an important contrast 
mechanism for MRI in the field of molecular and cellular imag-
ing. The recent study of CEST in PD focused on the gray matter 
of midbrain and basal ganglia. The result indicated the potential 
of the CEST signal as a marker of PD (Li et al., 2014).
The aim of this study was to compare the diagnostic efficiency 
of the DTI and CEST techniques in PD, by evaluating the changes 
of substantia nigra and striatum (globus pallidus, putamen, and 
caudate).
MaTerials anD MeThODs
Patients and controls
A total of 23 PD patients (13 men and 10 women; mean age, 
65.5 years; range, 46–77 years; 12.2 ± 4.3 years of education) and 
23 age- and education-matched normal controls (13 men and 10 
women; mean age, 64.3 years; range, 50–72 years; 12.8 ± 3.6 years 
of education) were recruited in this study. All patients were right-
handed. Informed consent was acquired from each subject prior 
to participation in this study. The study was approved by the local 
Institutional Review Board.
Parkinson’s disease diagnosis was confirmed by an experienced 
movement disorder specialist according to published criteria 
(Hughes et al., 1992, 2001). The patients fulfilled the UK Brain 
Bank criteria for idiopathic PD. All PD patients were assessed 
with the Hoehn and Yahr (H&Y) scale by the same movement 
disorder specialist after overnight withdrawal of antiparkinson 
medication for at least 12 h.
The exclusion criteria for subjects in this study were as fol-
lows: head trauma; central nervous system infection; a history of 
stroke; exposure to anti-dopaminergic drugs; or other neurologic 
or psychiatric diseases and any structural abnormalities on brain 
magnetic resonance images.
Mri acquisition
All subjects were imaged on a 3T Philips MRI system (Achieva 
3.0T; Philips Medical Systems, Best, The Netherlands), with a 
dual-channel body coil for transmission and an eight-channel 
sensitivity-encoding coil for reception. Pencil beam second-order 
shimming was employed. The PD patients were scanned shortly 
after the neurological assessment. Routine images, including 
axial T2-weighted, T1-weighted, and fluid-attenuated inversion 
recovery (FLAIR), were acquired first to exclude structural 
abnormality.
CEST/APT Imaging
The CEST/APT imaging sequence was based on a pseudo-
continuous wave, off-resonance RF irradiation (saturation dura-
tion = 200 ms × 4; inter-pulse delay, 10 ms; power level = 2 μT) 
and a single-shot, turbo-spin-echo readout. The parameters 
were as follows: repetition time = 3000 ms; echo time = 7.9 ms; 
turbo-spin-echo factor = 54; field of view = 230 mm × 221 mm; 
matrix = 105 × 100; and slice thickness = 6 mm. Two transverse 
slices of the head were acquired, including the basal ganglia and 
midbrain. A multi-offset, multi-acquisition CEST/APT imaging 
protocol, as reported before (Li et  al., 2014), was used. The 31 
offsets were 0, ±0.25, ±0.5, ±0.75, ±1 (2), ±1.5 (2), ±2 (2), ±2.5 
(2), ±3 (2), ±3.25 (2), ±3.5 (8), ±3.75 (2), ±4 (2), ±4.5, ±5, and 
±6  ppm (the values in parentheses represented the number of 
acquisitions, which was 1, if not specified). An unsaturated image 
was acquired for the signal normalization. The acquisition time 
was about 3 min per slice.
Diffusion-Tensor Imaging
The parameters were as follows: repetition time = shortest (actual 
TR = 5472 ms); echo time = shortest (actual TE: 93 ms); b val-
ues = 0, 1000 s/mm2; diffusion gradient directions = 31; field of 
view = 240 mm × 240 mm; matrix = 128 × 128; number of excita-
tions = 1; slice thickness = 3 mm; gap = 0; and slice number = 40. 
The acquisition time was about 7.5 min.
imaging Processing
CEST/APT Imaging
The APT imaging analysis was performed using in-house devel-
oped software, based on the Interactive Data Language (IDL, ITT 
Visual Information Solutions, Boulder, CO, USA) environment. 
The measured magnetization transfer spectra (Ssat/S0, in which 
Ssat and S0 are the signal intensities with and without selective 
RF irradiation, respectively, plotted as a function of saturation 
frequency offset, relative to water) were corrected for field 
inhomogeneity effects on a pixel-by-pixel basis. CEST imaging 
is usually quantified through the magnetization transfer ratio 
FigUre 2 | examples of the definition of the regions of interest for 
quantitative analysis. (a) substantia nigra (green), (B) globus pallidus (blue), 
putamen (yellow) and caudate (red). FA and MD were measured for each 
region. The values of each side were recorded as separate samples.
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(MTR  =  1  −  Ssat/S0) asymmetry (MTRasym) analysis with 
respect to the water resonance:
 MTR offset MTR offset MTR offset
                 
asym( ) ( ) ( )= + − −
          offset offset)sat sat= − − + S S S( ) ( / .0
 (1)
We defined the total CEST signal intensity, MTRasymtotal , as the 
integral of the MTRasym spectrum in the range of 0–4 ppm.
Specifically for APT imaging, we have:
 MTR ppm APTR MTR ppmasym asym( . ) ( . ),3 5 3 5= + ′  (2)
where APTR is the proton transfer ratio for the amide protons 
associated with mobile cellular proteins and peptides in tissue. 
MTRasym′  was previously thought to be the inherent MTRasym of 
the solid-phase magnetization transfer effect (Zhou et al., 2008). 
However, the semi-solid conventional magnetization transfer 
effect was thought to be symmetrical around the water resonance 
due to a very broad-spectrum distribution. Several recent studies 
suggest that MTRasym′  could be dominated by the possible intra-
molecular or intermolecular nuclear Overhauser enhancement 
effect of the upfield non-exchangeable protons (such as aliphatic 
protons) of mobile to relatively less mobile cellular macromol-
ecules and metabolites (Zhou et al., 2013a; Heo et al., 2015). To 
account for these confounding factors, the MTRasym(3.5  ppm) 
images calculated by Eq. 2 are, in principle, APT-weighted images.
The quantitative image analysis was performed by two 
radiologists (CL and RW, who had 5 and 10 years of experience 
in brain imaging, respectively). The FLAIR images were used 
as the anatomical reference to draw regions of interest (ROIs; 
substantia nigra, globus pallidus, putamen, and caudate of both 
hemispheres) (Figure 1). MTRasym(3.5 ppm) and MTRasym
total  were 
measured for each region. The values of each side were recorded 
as a separate sample.
Diffusion-Tensor Imaging
Imaging analysis was carried out using FSL 4.0 software package 
(http://www.fmrib.ox.ac.uk/fsl). The first preprocessing step was 
to correct the motion effect and image distortion due to the eddy 
FigUre 1 | examples of the definition of the regions of interest for 
quantitative analysis. (a) substantia nigra (green), (B) globus pallidus (blue), 
putamen (yellow) and caudate (red). MTRasym(3.5 ppm) and  MTRasym
total  were 
measured for each region. The values of each side were recorded as 
separate samples.
current. Next, skull stripping with the brain extraction tool (BET) 
was applied and brain masks were generated. Third, tensors were 
determined using DTIFIT, producing FA and MD maps.
We used ROI-based analysis in this study. The quantitative 
image analysis was performed by two radiologists (CL and RW), 
the same as CEST/APT imaging analysis. The b = 0 images were 
used as the anatomical reference to draw regions of interest 
(substantia nigra, globus pallidus, putamen, and caudate of both 
hemispheres) (Figure 2). FA and MD values were measured for 
each region. The values of each side were recorded as a separate 
sample. We covered the regions we concerned as much as pos-
sible, just the same as we do in CEST/APT analysis, to ensure the 
ROIs in CEST/APT and DTI were identical as much as possible.
statistical analysis
All data were analyzed using the statistical package SPSS16.0. 
The average CEST imaging intensities [MTRasym(3.5  ppm) and 
MTRasym
total ] and corresponding 95% confidence intervals were 
calculated for each region, as well as MD and FA values from DTI. 
Independent-samples t-tests were used to compare the differences 
in the parameters of CEST and DTI between PD patients and 
normal controls. Meanwhile, the PD patients were divided into two 
groups according to the H&Y stages (early stage: H&Y stages 1 and 
2 vs. advanced stage: H&Y stages ≥2.5). The values of the param-
eters at different stages were also compared with one-way ANOVA. 
The level of significance was set at P < 0.05. We used post hoc tests 
to make multiple comparisons between every two groups. Tests of 
homogeneity of variances P values were used before the multiple 
comparisons. Tukey post hoc tests would be used with P ≥ 0.05, 
while Games-howell post hoc tests would be used with P < 0.05.
resUlTs
substantia nigra
Table 1 shows the comparison of CEST/APT and DTI values in 
the substantia nigra for PD patients and for normal controls. The 
MTRasym(3.5 ppm) and MTRasym
total  values from CEST/APT, as well 
as the FA values from DTI, all showed significant differences on the 
FigUre 3 | (a) FLAIR image, (B) APT-weighted image, (c) FA image, and (D) MD image of a PD patient (female; 53 years old; H&Y stage 3). (e) FLAIR image, (F) 
APT-weighted image, (g) FA image, and (h) MD image of a normal control (male; 65 years old). The CEST/APT imaging acquisition protocol provided B0 
inhomogeneity-corrected, APT-weighted images with sufficient signal-to-noise ratios. The APT-weighted intensities in regions of the substantia nigra (black arrow) were 
lower in PD patient than in normal control. The FA values in regions of the substantia nigra (black arrow) seemed to be similar for this PD patient and normal control 
though they have group differences. The MD value in regions of the substantia nigra (black arrow) also seemed to be similar for this PD patient and normal control.
TaBle 1 | comparisons of cesT/aPT and DTi parameters values in 
the substantia nigra for Parkinson’s disease (PD) patients and normal 
controls (mean ± 95% ci).
normal (n = 23) PD (n = 23) P values
CEST/APT MTRasym(3.5 ppm) 1.25 ± 0.18 0.89 ± 0.15 0.003
MTRasym
total 3.45 ± 0.44 2.45 ± 0.50 0.004
DTI FA 0.36 ± 0.02 0.32 ± 0.02 <0.001
MD 0.68 ± 0.02 0.70 ± 0.03 0.400
MTRasym(3.5 ppm) was quantified by % water signal intensity. MTRasym
total  was defined as 
the integral of the MTRasym spectrum in the range of 0–4 ppm. FA, fractional anisotropy; 
MD, mean diffusivity. Bold indicates significant change.
October 2015 | Volume 7 | Article 1984
Li et al. CEST and DTI of PD
Frontiers in Aging Neuroscience | www.frontiersin.org
substantia nigra in PD patients, compared with normal controls. 
Figure 3 shows the example images in regions of the substantia 
nigra of a PD patient and a normal control. The value difference 
between PD patient and normal control can be obviously seen in 
regions of the substantia nigra (black arrow) in APT-weighted 
image. However, the FA value difference between PD patient and 
normal control seemed to be unapparent in the substantia nigra 
(black arrow) though they have group differences.
Table 2 compares the CEST/APT and DTI parameters values 
in the substantia nigra for normal controls and for early-stage 
and advanced-stage PD patients. The MTRasym(3.5  ppm) value, 
the MTRasym
total  value and FA value all showed significant differ-
ences between normal controls and advanced-stage PD. The 
MTRasym(3.5 ppm) value of the substantia nigra even decreased 
significantly from the normal controls to the early-stage PD 
(P =  0.032). A progressive decrease can be seen from normal 
controls, early-stage PD patients to late-stage PD patients for the 
MTRasym(3.5 ppm) value, the MTRasym
total  value and FA value. No 
significant differences were found for MD values.
striatum (globus Pallidus, Putamen,  
and caudate)
Tables 3–5 show the comparisons of CEST/APT and DTI param-
eters values in the globus pallidus, putamen, and caudate for PD 
patients and normal controls, respectively. The MTRasym(3.5 ppm) 
values of the putamen and caudate were significantly higher in 
PD patients than in normal controls (P = 0.010 and P = 0.009, 
respectively). The MTRasym(3.5 ppm) value of the globus pallidus 
was also higher in PD patients than in normal controls, but the 
difference was not significant (P = 0.125). The MTRasymtotal  of the 
globus pallidus, putamen and caudate were also higher in PD 
patients than in normal controls, but no significant differences 
were found (P = 0.259, P = 0.119, and P = 0.573, respectively). 
No significant differences were found for the FA and MD values 
of the globus pallidus, putamen, and caudate between PD patients 
and normal controls.
Figure 4 shows the example images in the striatum of a PD 
patient and a normal control. The value difference between PD 
patient and normal control can be obviously seen in regions of 
the striatum (black arrow) in APT-weighted image, while no 
significant differences were found for the FA and MD images 
(black arrow).
Tables 6–8 further compare CEST/APT and DTI values in the 
globus pallidus, putamen, and caudate for normal controls and 
early-stage and advanced-stage PD patients. It can be seen that 
the MTRasym(3.5  ppm) intensities of the putamen and caudate 
increased significantly from the normal controls to the early-stage 
PD (P = 0.016 and P < 0.001, respectively). The MTRasym(3.5 ppm) 
value of the globus pallidus was also higher in early-stage PD 
patients than in normal controls, but the difference was not 
significant (P = 0.212). Meanwhile, the MTRasym(3.5 ppm) of the 
TaBle 2 | cesT/aPT and DTi parameters values in the substantia nigra for normal controls and PD patients at different stages.
normal 
(n = 23)
early-stage 
PD (n = 12)
advanced-stage 
PD (n = 11)
Tests of 
homogeneity of 
variances P values
anOVa Multiple comparisons P values 
(95% confidence interval)
df F P values
CEST/APT MTRasym(3.5 ppm) 1.25 ± 0.18 0.96 ± 0.14 0.81 ± 0.29 0.035 2 5.248 0.007 0.032 (0.02, 0.54), 0.599 (−0.23, 
0.54), 0.032 (0.03, 0.84)
MTRasym
total 3.45 ± 0.44 2.68 ± 0.50 2.21 ± 0.95 0.097 2 4.980 0.009 0.141 (−0.19, 1.73), 0.576 
(−0.65, 1.59), 0.010 (0.26, 2.23)
DTI FA 0.36 ± 0.02 0.34 ± 0.02 0.31 ± 0.03 0.790 2 9.630 <0.001 0.149 (−0.01, 0.05), 0.072 
(−0.01, 0.07), <0.001 (0.03, 
0.09)
MD 0.68 ± 0.02 0.69 ± 0.03 0.70 ± 0.05 0.003 2 0.429 0.653 0.837 (−0.06, 0.04), 0.943 
(−0.09, 0.07), 0.750 (−0.10, 0.05)
MTRasym(3.5 ppm) was quantified by % water signal intensity. MTRasym
total  was defined as the integral of the MTRasym spectrum in the range of 0–4 ppm. FA, fractional anisotropy; MD, 
mean diffusivity. Three P values in multiple comparisons corresponded to the results between normal controls and early-stage PD patients, between early-stage and advanced-stage 
PD patients, as well as between normal controls and advanced-stage PD patients, respectively. Bold indicates significant change.
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DiscUssiOn
In this study, we used two techniques, CEST/APT and DTI, to 
evaluate PD. The regions we focused on included the substantia 
nigra and striatum, for they are the main regions involved in PD. 
We aimed to compare the changes of these regions in PD by these 
two techniques and find out which can provide more information 
in the assessment of PD. To our knowledge, very few previous 
reports evaluated PD with CEST/APT and the present study was 
the first time to compare CEST and DTI in PD patients.
Chemical exchange saturation transfer imaging is a novel 
molecular MRI technique that can detect endogenous, low-
concentration chemicals in tissue non-invasively (Cai et  al., 
2012; Haris et al., 2013; Walker-Samuel et al., 2013; Harston et al., 
2015). More specifically, APT imaging (a type of CEST imaging, 
sensitive to amide protons resonating at 3.5  ppm from water) 
was designed to detect mobile (cytosolic) proteins and peptides. 
Previous study has indicated the possibility of using CEST/APT 
in the diagnosis of PD (Li et  al., 2014). DTI based upon the 
diffusivity of water molecules has typically been used to study 
white matter tract. Although the concerned regions in this study 
are not the typical targets for DTI studies, diffusion anisotropy 
changes in gray matter have been reported in aging (Pfefferbaum 
et al., 2010), brain maturation (Mukherjee et al., 2002), and other 
neurological disorders (Bozzali et al., 2002). Thus, analyses have 
performed on gray matter area changes of PD in some studies and 
the results seemed to be variable.
substantia nigra result analysis
The substantia nigra showed significantly lower MTRasym(3.5 ppm) 
signal intensities and lower total CEST signal intensities in PD 
patients than in normal controls, which may suggest that the 
changes could be attributed to the loss of dopaminergic neu-
rons or to the depletion of some chemicals with fast exchange 
protons, such as dopamine. This result is similar to the previous 
study (Li et al., 2014). FA values of the substantia nigra showed 
significant difference in PD patients, which may result from the 
loss of dopaminergic neurons and injury of axons. This result 
agreed with some publications (Vaillancourt et al., 2009; Du et al., 
2012; Skorpil et al., 2012), but in contrast to some other reports 
showing small or no PD induced decreased FA (Menke et  al., 
TaBle 3 | comparisons of cesT/aPT and DTi parameters values in the 
globus pallidus for Parkinson’s disease (PD) patients and normal controls 
(mean ± 95% ci).
normal (n = 23) PD (n = 23) P values
CEST/APT MTRasym(3.5 ppm) 0.68 ± 0.17 0.84 ± 0.12 0.125
MTRasym
total 2.20 ± 0.29 2.48 ± 0.38 0.259
DTI FA 0.25 ± 0.01 0.24 ± 0.02 0.122
MD 0.70 ± 0.03 0.72 ± 0.03 0.227
MTRasym(3.5 ppm) was quantified by % water signal intensity. MTRasym
total  was defined as 
the integral of the MTRasym spectrum in the range of 0–4 ppm. FA, fractional anisotropy; 
MD, mean diffusivity. 
TaBle 4 | comparisons of cesT/aPT and DTi parameters values in 
the putamen for Parkinson’s disease (PD) patients and normal controls 
(mean ± 95% ci).
normal (n = 23) PD (n = 23) P values
CEST/APT MTRasym(3.5 ppm) 0.83 ± 0.13 1.06 ± 0.12 0.010
MTRasym
total 2.68 ± 0.25 3.01 ± 0.34 0.119
DTI FA 0.14 ± 0.01 0.14 ± 0.01 0.520
MD 0.72 ± 0.01 0.73 ± 0.01 0.142
MTRasym(3.5 ppm) was quantified by % water signal intensity. MTRasym
total  was defined as 
the integral of the MTRasym spectrum in the range of 0–4 ppm. FA, fractional anisotropy; 
MD, mean diffusivity. Bold indicates significant change.
TaBle 5 | comparisons of cesT/aPT and DTi parameters values in 
the caudate for Parkinson’s disease (PD) patients and normal controls 
(mean ± 95% ci).
normal (n = 23) PD (n = 23) P values
CEST/APT MTRasym(3.5 ppm) 0.84 ± 0.17 1.14 ± 0.14 0.009
MTRasym
total 2.79 ± 0.21 2.90 ± 0.35 0.573
DTI FA 0.16 ± 0.01 0.15 ± 0.01 0.563
MD 0.74 ± 0.03 0.75 ± 0.01 0.546
MTRasym(3.5 ppm) was quantified by % water signal intensity. MTRasym
total  was defined as 
the integral of the MTRasym spectrum in the range of 0–4 ppm. FA, fractional anisotropy; 
MD, mean diffusivity. Bold indicates significant change.
caudate for PD patients showed a significant decrease from the 
early stage to the advanced stage (P = 0.013).
No significant differences were found for the MTRasym
total values, 
FA values, and MD values.
TaBle 6 | cesT/aPT and DTi parameters values in the globus pallidus for normal controls and PD patients at different stages.
normal 
(n = 23)
early-stage 
PD (n = 12)
advanced-stage 
PD (n = 11)
Tests of 
homogeneity of 
variances P values
anOVa Multiple comparisons P values 
(95% confidence interval)
df F P values
CEST/APT MTRasym(3.5 ppm) 0.68 ± 0.17 0.89 ± 0.14 0.78 ± 0.20 0.065 2 1.470 0.236 0.212 (−0.51, 0.09), 0.739 
(−0.24, 0.45), 0.703 (−0.41, 0.20)
MTRasym
total 2.20 ± 0.29 2.60 ± 0.58 2.34 ± 0.53 0.827 2 0.927 0.400 0.366 (−1.09, 0.30), 0.731 
(−0.55, 1.07), 0.889 (−0.85, 0.58)
DTI FA 0.25 ± 0.01 0.23 ± 0.03 0.24 ± 0.03 0.162 2 1.284 0.282 0.294 (−0.01, 0.06), 0.921 
(−0.05, 0.04), 0.565 (−0.02, 0.05)
MD 0.70 ± 0.03 0.71 ± 0.04 0.73 ± 0.04 0.751 2 1.076 0.345 0.849 (−0.07, 0.04), 0.691 
(−0.09, 0.04), 0.312 (−0.10, 0.02)
MTRasym(3.5 ppm) was quantified by % water signal intensity. MTRasym
total  was defined as the integral of the MTRasym spectrum in the range of 0–4 ppm. FA, fractional anisotropy; MD, 
mean diffusivity. Three P values in multiple comparisons corresponded to the results between normal controls and early-stage PD patients, between early-stage and advanced-stage 
PD patients, as well as between normal controls and advanced-stage PD patients, respectively. Bold indicates significant change.
FigUre 4 | (a) FLAIR image, (B) APT-weighted image, (c) FA image, and (D) MD image of a PD patient (male; 74 years old; H&Y stage 2.5). (e) FLAIR image, (F) 
APT-weighted image, (g) FA image, and (h) MD image of a normal control (male; 61 years old). The CEST/APT imaging acquisition protocol provided B0 
inhomogeneity-corrected, APT-weighted images with sufficient signal-to-noise ratios. The APT-weighted intensities in regions of the striatum (black arrow) were higher 
in PD patient than in normal control. The FA and MD values in regions of the striatum (black arrow) seemed to be similar for this PD patient and normal control.
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2010; Focke et al., 2011; Kim et al., 2013; Aquino et al., 2014), 
or even increased nigral FA in PD patients (Wang et al., 2011). 
For MD values of the substantia nigra, no significant changes 
were found in PD patients compared to normal controls, though 
they seemed to have an increase tendency in PD patients. This 
agreed with some previous reports (Karagulle Kendi et al., 2008; 
Du et  al., 2012; Aquino et  al., 2014) but disagreed with some 
other reports (Gattellaro et al., 2009; Prakash et al., 2012), which 
found increased nigral MD values. Potential factors contributing 
to this study heterogeneity may be technical aspects resulting 
limited quality of FA or MD measurements and different study 
population characteristics, such as disease severity, as Stefan said 
in their meta-analysis (Schwarz et  al., 2013). From our results, 
both CEST/APT and DTI parameters are able to differentiate PD 
from normal controls.
We further divided PD patients into two groups according to 
the H&Y stages (early stage: H&Y stages 1 and 2 vs. advanced 
stage: H&Y stages ≥2.5) to find out the CEST/APT and DTI 
changes in the substantia nigra in different stages of PD. The 
CEST intensity had a tendency to decrease gradually with the PD 
progression, no matter the MTRasym(3.5 ppm) signal intensities 
or the total CEST signal intensities. Meanwhile, the FA value also 
had similar decreased tendency in the progression of PD. As the 
FA value decrease in PD has been contributed to the continuous 
dopaminergic neurons loss, such results may provide us indirect 
evidence that CEST/APT can reveal the loss of dopaminergic 
neurons in PD (Kirik et al., 2002; Hodaie et al., 2007). However, 
the CEST/APT seemed to be superior to DTI in the further com-
parison of different groups. Significant differences were found 
for both MTRasym(3.5  ppm) and total CEST signal intensities 
between normal controls and advanced-stage PD. Moreover, the 
MTRasym(3.5 ppm) signal intensities of the substantia nigra has 
decreased significantly in PD patients even in early stage, which 
indicated the potential of CEST imaging to detect PD patients in 
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TaBle 7 | cesT/aPT and DTi parameters values in the putamen for normal controls and PD patients at different stages.
normal 
(n = 23)
early-stage 
PD (n = 12)
advanced-stage 
PD (n = 11)
Tests of 
homogeneity of 
variances P values
anOVa Multiple comparisons P values 
(95% confidence interval)
df F P values
CEST/APT MTRasym(3.5 ppm) 0.83 ± 0.13 1.12 ± 0.12 0.99 ± 0.20 0.279 2 4.142 0.019 0.016 (−0.54, −0.05), 0.500 
(−0.15, 0.43), 0.314 (−0.41, 0.10)
MTRasym
total 2.68 ± 0.25 3.10 ± 0.46 2.92 ± 0.55 0.038 2 1.427 0.245 0.237 (−1.05, 0.20), 0.849 
(−0.65, 1.03), 0.702 (−0.95, 0.48)
DTI FA 0.14 ± 0.01 0.14 ± 0.02 0.14 ± 0.01 0.260 2 0.250 0.779 0.766 (−0.02, 0.01), 0.954 
(−0.02, 0.02), 0.937 (−0.02, 0.02)
MD 0.72 ± 0.01 0.72 ± 0.02 0.74 ± 0.02 0.505 2 2.046 0.135 0.889 (−0.03, 0.02), 0.360 
(−0.05, 0.01), 0.116 (−0.05, 0.01)
MTRasym(3.5 ppm) was quantified by % water signal intensity. MTRasym
total  was defined as the integral of the MTRasym spectrum in the range of 0–4 ppm. FA, fractional anisotropy; MD, 
mean diffusivity. Three P values in multiple comparisons corresponded to the results between normal controls and early-stage PD patients, between early-stage and advanced-stage 
PD patients, as well as between normal controls and advanced-stage PD patients, respectively. Bold indicates significant change.
TaBle 8 | cesT/aPT and DTi parameters values in the caudate for normal controls and PD patients at different stages.
normal 
(n = 23)
early-stage 
PD (n = 12)
advanced-stage 
PD (n = 11)
Tests of 
homogeneity of 
variances P values
anOVa Multiple comparisons P values 
(95% confidence interval)
df F P values
CEST/APT MTRasym(3.5 ppm) 0.84 ± 0.17 1.35 ± 0.14 0.91 ± 0.25 0.246 2 8.084 0.001 <0.001 (−0.82, −0.20),0.013 
(0.08, 0.80), 0.859 (−0.39, 0.25)
MTRasym
total 2.79 ± 0.21 3.06 ± 0.48 2.73 ± 0.54 0.008 2 0.850 0.431 0.531 (−0.90, 0.35), 0.601 
(−0.51, 1.18), 0.974 (−0.63, 0.75)
DTI FA 0.16 ± 0.01 0.16 ± 0.02 0.15 ± 0.01 0.099 2 0.514 0.600 1.000 (−0.02, 0.02), 0.684 
(−0.01, 0.03), 0.604 (−0.01, 0.03)
MD 0.74 ± 0.03 0.75 ± 0.02 0.74 ± 0.02 0.578 2 0.293 0.746 0.726 (−0.07, 0.04), 0.885 
(−0.05, 0.07), 0.977 (−0.06, 0.05)
MTRasym(3.5 ppm) was quantified by % water signal intensity. MTRasym
total  was defined as the integral of the MTRasym spectrum in the range of 0–4 ppm. FA, fractional anisotropy; MD, 
mean diffusivity. Three P values in multiple comparisons corresponded to the results between normal controls and early-stage PD patients, between early-stage and advanced-stage 
PD patients, as well as between normal controls and advanced-stage PD patients, respectively. Bold indicates significant change.
early stage. In the other hand, FA values only showed significant 
differences between normal controls and advanced-stage PD 
and no significant differences were found for MD although they 
seemed to increase gradually in PD progression.
striatum (globus Pallidus, Putamen, and 
caudate) result analysis
For CEST/APT, the MTRasym(3.5 ppm) signal intensities and total 
CEST signal intensities of the globus pallidus, putamen, and cau-
date were higher in PD patients than in normal controls though 
the changes in some regions were not significant. This may be 
associated with increased cytosolic proteins and peptides, as 
expected (Braak et al., 1999; Tong et al., 2010). When dividing PD 
patients into early stage and advanced stage, the CEST intensity 
changes for the globus pallidus, putamen, and caudate were more 
complicated. It seemed that both the MTRasym(3.5  ppm) signal 
intensities and the total CEST signal intensities reached to the 
peak at early stage and later dropped at advanced stage. For the 
putamen and caudate, the MTRasym(3.5  ppm) signal intensities 
even showed significant increases in early stage. This result is 
similar to the previous study (Li et al., 2014).This indicated CEST 
intensities in these three regions may play a more important part 
in the early diagnosis of PD, even though we are not sure the 
exact mechanism of their changes now. We can only presume 
the CEST intensities increased in early stage due to the increased 
of abnormal cytoplasmic proteins (such as α-synuclein) (Braak 
et  al., 1999; Tong et al., 2010) and their decreases in advanced 
stage may associate with the neurons loss with PD progression or 
the treatment effect.
Compared with CEST/APT, DTI results seemed not promis-
ing. No significant differences were found between PD patients 
and normal controls in these regions, no matter MD or FA. Even 
when we further divided PD patients into two groups (early 
stage and advanced stage) to compare the FA and MD values of 
three groups, no significant differences were found for every two 
groups comparisons. Such results accorded with previous reports 
(Nicoletti et al., 2006; Gattellaro et al., 2009; Focke et al., 2011). In 
contrast, some studies got the result that these regions may have 
higher MD values (Kim et al., 2013) or lower FA values (Zhan 
et al., 2012) in PD. The reason for this inconsistency is not clear. 
However, we presume that the difference of PD population, scan 
protocol or the method of postprocessing including thresholding 
of FA and setting of significance level may be the potential factors.
comparison of cesT/aPT imaging and 
DTi
From our results, CEST/APT imaging had provided more informa-
tion than DTI in the differentiation of PD. Multiple regions revealed 
significant changes in the four regions in PD compared to normal 
controls by the parameters of CEST/APT imaging, while DTI only 
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suggested the FA changes in the substantia nigra. Meanwhile, mul-
tiple regions, including the substantia nigra, putamen, and caudate, 
showed significant MTRasym(3.5 ppm) changes even in early stage 
of PD, which indicated their potential in the early diagnosis of PD. 
Moreover, the MTRasym(3.5  ppm) values of the caudate showed 
significant changes from early stage to advanced stage of PD, 
supplying information in the evaluation of PD progression. The 
FA values of the substantia nigra also decreased significantly from 
normal controls to advanced-stage PD, but no other significant 
changes were found for DTI neither in the comparison of normal 
controls and early-stage PD, nor the comparison of early stage 
and advanced stage. Though the results may be influenced by the 
patient population, scan protocol or postprocessing, which may 
cause the underestimation of the DTI utility in PD evaluation in 
this study, our preliminary results indeed revealed the superior 
utility of CEST/APT imaging in the evaluation of PD.
There were some limitations to this study. First, owing to 
the limitation of the single-slice acquisition protocol for CEST/
APT imaging, only two slices were acquired in this study. Thus, 
we can evaluate the MRI signal changes in these two slices and 
other regions could not be included in the present study. This 
shortage may be overcome by 3D imaging acquisition sequence 
in the future, which has been reported (Zhou et  al., 2013b). 
Second, the ROIs for CEST/APT imaging and DTI were selected 
respectively, which may cause mismatch of the ROIs selection. 
Besides, the limited resolution of CEST/APT imaging brought 
some difficulty for us to select these four small regions exactly 
for the quantitative analysis. This may influence the comparison 
result to some extent. Third, the sample number in the present 
study was relatively small and further studies with large sample 
analysis are needed to confirm these results.
In conclusion, CEST MR imaging provided multiple CEST 
signal differences in the regions of substantia nigra and striatum 
in PD and may be superior to DTI in the diagnosis and severity 
evaluation of PD. CEST MR imaging has the potential to differen-
tiate PD patients in the early stage and to evaluate the progression 
of PD. In the coming work, more cases should be collected to 
confirm the utility of CEST MR imaging. Also, the mechanisms 
underlying such results should be studied.
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